Drugs / MET-2
MET-2
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03660748 | Oct 2018 → Jan 2020 | obesity disorder | NuBiyota | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT04052451 | May 2019 → May 2020 | mixed anxiety and depressive disorder | NuBiyota | Completed | No outcome recorded |
| Phase 1 | NCT03832400 | Feb 2019 → Mar 2020 | ulcerative colitis | NuBiyota | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT06214403 | Jul 2026 → Jan 2028 | gram-negative bacterial infections | University Health Network, Toronto | Withdrawn | No outcome recorded |
| Phase 2 | NCT04602715 | Apr → Jun 2021 | anxiety, major depressive disorder | NuBiyota | Unknown | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MET-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03832400 ↗ |
| Known as | Microbial Ecosystem Therapeutic (MET)-2 | “This study explores the use of an alternative gut repopulation treatment to fecal microbiota transplantation, known as Microbial Ecosystem Therapeutic (MET)-2, as an...” PMID 34550085 ↗ Sep 2021 |
| Known as | Microbial Ecosystem Therapeutic-2 | “This study examines the safety and efficacy of a fecal transplant alternative, Microbial Ecosystem Therapeutic-2 (MET-2), in improving symptoms of depression.” PMID 40116713 ↗ Mar 20251“The investigational product, Microbial Ecosystem Therapeutic-2 (MET-2), is a defined microbial community derived from healthy donor stool.” NCT06214403 ↗ |
| Modality | Other / unclassified | “Ingestion of a novel human microbiome preparation” NCT03660748 ↗ |
| Route | Oral | “via an oral capsule” NCT03832400 ↗ |